In 200th anniversary of Kingdom of Japan, ties with Kingdom of the Netherlands are stronger than ever.

The Netherlands is the largest destination of Japanese investment among European Union countries today.

---Masaru Tsuji

Japans Botschafter in den Niederlanden

---Gereon Malek, Managing Director and Gert-Jan Manes (R), Owners of ELIANT (the Dutch & Japanese Trade Federation)

Netherlands

---PREGER ELEN

Business Management Center of Japan

---THERE IS A VITAL CONCEPT

1. There is a strong tradition of mutual respect for each other's culture and people. The Dutch and Japanese companies work together successfully in a wide range of sectors, such as agriculture, machinery, electronics and construction.

2. Both countries have a strong tradition of corporate social responsibility. The Dutch and Japanese companies have a strong record of charitable giving, with a focus on education and healthcare.

3. Both countries have a strong tradition of innovation. The Dutch and Japanese companies have a strong record of innovation and are leaders in many industries, such as technology and healthcare.

4. Both countries have a strong tradition of human rights. The Dutch and Japanese companies have a strong record of upholding human rights, with a focus on freedom of speech and the press, and the protection of vulnerable groups, such as women and children.

---Tomoko Ueda

Japanese Investment Promotion Office
Pharma star shines brightly at 10-year mark

T hrough its European Miblia East and Africa base in new in London, Astellas Pharma has always been intimately connected to the Netherlands. It even made a move. It rose from the merger of Fujisawa and Yamanouchi, whose European operations had been built up all on acquisition of the drug division of the Dutch chemical group Koninklijke DSM N.V. back in 1991.

This year, Astellas Pharma celebrates its 10th anniversary in the country. Since its approval in 2012, the company has continued to innovate, recently expanding its business operations to include the development of new anti-cancer treatments. The company has also recently announced the acquisition of Fujisawa and Yamanouchi, which will strengthen its position in the European pharmaceutical market.

In this article, we will explore the history of Astellas Pharma’s European operations and examine the company’s role in the European pharmaceutical industry. We will also look at the company’s future prospects and potential for growth.

**Astellas Pharma’s European Operations**

Astellas Pharma’s European headquarters are located in Leiden, Netherlands. The company was founded in 1991 as a result of the merger of Fujisawa and Yamanouchi. Since then, the company has continued to grow and expand its operations across Europe. Astellas Pharma is currently one of the largest pharmaceutical companies in Europe, with sales exceeding €10 billion in 2019.

**Astellas Pharma’s European R&D Headquarters**

Astellas Pharma’s European R&D headquarters is located in Leiden, southwest of Amsterdam. The company’s R&D center focuses on the development of new drugs and therapies, with a particular emphasis on oncology, rare diseases, and cardiovascular diseases.

**Astellas Pharma’s European Production Sites**

Astellas Pharma has production sites located in various European countries, including the Netherlands, Italy, and Spain. These production sites are responsible for the manufacture of a wide range of pharmaceutical products, including small-molecule drugs, biologics, and gene therapies.

**Astellas Pharma’s European Sales and Marketing Team**

Astellas Pharma has a strong sales and marketing team in Europe, with offices located in major cities across the continent. The company’s sales and marketing team is responsible for the promotion and distribution of its products, as well as the development of new sales strategies.

**Astellas Pharma’s European Regulatory Affairs Team**

Astellas Pharma has a dedicated team of regulatory affairs professionals who work to ensure that the company’s products meet all relevant regulatory requirements. This team is responsible for the submission of regulatory applications to national and international regulatory authorities, as well as the management of post-market surveillance and safety monitoring.

**Astellas Pharma’s Future Prospects**

Astellas Pharma is well-positioned for continued growth in the European pharmaceutical market. The company has a strong product portfolio, with several new drugs and therapies in development, and a strong pipeline of potential new products.

**Conclusion**

Astellas Pharma is a leading pharmaceutical company with a strong presence in the European market. With a focus on innovation, the company continues to develop new drugs and therapies, as well as expand its operations across Europe. As the European pharmaceutical industry continues to evolve, Astellas Pharma is well-positioned to continue its success in the region.

---

*Daniel van der Donk, MD, PhD*

Managing Director of Yokogawa in the Netherlands

---

*Astellas Pharma’s new European R&D headquarters in Leiden, the country’s first BREED-certified sustainable chemistry lab.*

---

*Mr. Ikuo Kooijman is working to improve this general image. “The only thing that will safeguard our future growth is to keep developing new products and to maintain healthy heads,” he says. [www.astellas.eu]*

---

*The Draft Court of Keio University in Easakawa is a partnership between TenCate and the Jusla Court Foundation.*

---

*TenCate’s digital injet (drop-on-demand technique) for outdoor and protective fabrics.*
Drug specialist provides global pharma players with key tools for efficient development

Some pharmaceutical companies come to us looking for the right method to develop their drugs. We provide them with innovative techniques we have created to develop their products in a more economic way.

— ADAM COHEN
CEO of the CHDR

Japanese EMEA HQ celebrates decade of success

As we represent Mimaki’s most important market outside Japan, we need to handle customer feedback efficiently and meticulously.

— SHANE SAGANE
Managing Director
Mimaki Europe

Japanese EMEA HQ celebrates decade of success

On its 10th year as regional headquarters of the international group’s operations in Europe, the Middle East and Africa (EMEA), Mimaki Europe’s resilient corporate culture, as well as its dedication to its partners across the continent, stand out as key aspects of a successful decade.

As we represent Mimaki’s most important market outside Japan, we need to handle customer feedback efficiently and meticulously.

— SHANE SAGANE
Managing Director
Mimaki Europe

The development of new research programs and its work in progressive early stage clinical trials continues to foster a spirit of growth within the CHDR, as well as processing its status as a global player in the bioscience sector.

www.chdr.nl

WWW.WORLDEYEREPORT.COM